The combined use of these agents with a GLP-1 agonist might have a dramatic effect on improving the hepatocyte inflammatory response in NASH, as does the addition of Ezetimibe (Zetia) to HMGR inhibitors [146,147]. The gene discussed is HMGA1; the disease is metabolic dysfunction-associated steatohepatitis.